Abstract:Background Preeclampsia is characterized by maternal endothelial activation and placental dysfunction. Imbalance in maternal angiogenic and vasoactive factors has been linked to the pathophysiology. The contribution of the placenta as a source to these factors remains unclear. Furthermore, little is known about fetal angiogenic and vasoactive proteins and the relation between maternal and fetal levels. Objectives We describe Placental growth factor (PGF), soluble Fms-like tyrosine kinase 1 (sFLT1), soluble Endoglin (sENG), as well as Endothelin 1, 2 and 3 (EDN1, EDN2 and EDN3) in five vessels in healthy pregnancies, early onset (EOPE) and late onset (LOPE) preeclampsia. Specifically, we aimed to 1) compare protein abundance in vessels at the maternal-fetal interface between EOPE, LOPE and healthy pregnancies, 2) describe placental uptake and release of proteins, and 3) describe protein abundance in the maternal vs fetal circulations. Methods Samples were collected from the maternal radial artery, uterine vein and antecubital vein as well as the fetal umbilical vein and artery in 75 healthy and 37 preeclamptic mother-fetus pairs (including 19 EOPE and 18 LOPE), during scheduled cesarean delivery. This method allows estimation of placental release and uptake of proteins by calculation of venoarterial differences on each side of the placenta. The microarray based SomaScan assay quantified the proteins. Results Abundance of sFLT1 and EDN1 was higher in the maternal vessels in preeclampsia as compared to healthy pregnancies, with highest abundance in EOPE. PGF was lower in the maternal vessels in EOPE as compared to both healthy and LOPE. Maternal EDN2 was higher in preeclampsia, with LOPE having the highest abundance. Our model confirmed placental release of PGF and sFLT1 to the maternal circulation in all groups. The placenta released sFLT1 into the fetal circulation in healthy and LOPE pregnancies. Fetal EDN1 and sFLT1 were higher in early onset preeclampsia, whereas sENG and EDN3 were lower in both preeclampsia groups, compared to healthy. Across groups, abundances of PGF, sFLT1 and EDN3 were higher in the maternal artery as compared to the fetal umbilical vein, whereas EDN2 was lower. Conclusion Increasing abundance of maternal sFLT1 and EDN1 across the groups healthy, LOPE and EOPE combined with a positive correlation may suggest that these proteins are associated with the pathophysiology and severity of the disease. Elevated EDN1 in the fetal circulation in EOPE represents a novel finding. Long term effects of altered protein abundance in preeclampsia on fetal development and health remain unknown. Further investigation of these proteins' involvement in the pathophysiology and as treatment targets is warranted.

[Expression and Clinical Significance of Platelet-Derived Growth Factor A in Placenta of Pre-Eclampsia.].

Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia

Expression of Placental Vascular Growth Factor in Pregnancy-Induced Hypertension

[Expression of Fas and FasL in Serum and Placenta of Preeclamptic Pregnancy and Its Significance].

Increased Expression of Fatty Acid Binding Protein 4 in Preeclamptic Placenta and Its Relevance to Preeclampsia.

Declined placental PLAC1 expression is involved in preeclampsia.

Association of a Reduction of G-protein Coupled Receptor 30 Expression and the Pathogenesis of Preeclampsia

Effect of Vascular Endothelial Growth Factor on Pre-Eclampsia in Pregnant Rats

The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients

Relationship Between Expression of Vimentin, Type IV Collagen and Fibronectin in Human Placenta and Pregnancy Induced Hypertension

Serum and Placental Interleukin-18 Are Elevated in Preeclampsia

Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsia.

[Relationship Between Placenta Growth Factor and the Pathogenesis of Pregnancy Induced Hypertension Syndrome].

VEGF in the muscular layer of placental blood vessels: immuno-expression in preeclampsia and intrauterine growth restriction and its association with the antioxidant status

Placental Imbalance of Th1‐ and Th2‐type Cytokines in Preeclampsia

Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia

[Differential Expression of Extracellular Matrix Metalloproteinase Inducer in Normal Placenta and Preeclampsia Placenta].

Placental Endoglin Expression in Women with Severe Preeclampsia

Angiogenic and vasoactive proteins in the maternal-fetal interface in healthy pregnancies and preeclampsia

Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth

Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction